therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2023-4-3-7-14therapeutic-386Research ArticleОБЗОРЫREVIEWSКардиотоксичность антрациклинов и возможности ее коррекцииCodiotoxicity of anthraciclines and the possibilities of its correctionhttps://orcid.org/0000-0003-1510-9204КанорскийС. Г.KanorskiiS. G.

Канорский Сергей Григорьевич - доктор медицинских наук, проф., заведующий кафедрой терапии №2 факультета повышения квалификации и профессиональной переподготовки

Краснодар

Kanorskii Sergey G. - Dr. Sci. (Med.), Prof., Head of the Department of Therapy No. 2, Faculty of Advanced Training and Professional Retraining.

Krasnodar

kanorskysg@mail.ruПавловецВ. П.PavlovetsV. P.

Павловец Вадим Петрович - врач-кардиолог.

Краснодар

Pavlovets Vadim P. – cardiologist.

Krasnodar

v-pavlovec@mail.ruФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииРоссияKuban State Medical UniversityRussian FederationМногопрофильная клиника «МАММЭ»РоссияMAMMAE Multidisciplinary ClinicRussian Federation20232509202343714Copyright © Канорский С.Г., Павловец В.П., 20232023Канорский С.Г., Павловец В.П.Kanorskii S.G., Pavlovets V.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/386

Благодаря возросшей эффективности методов лечения в онкологии сердечно-сосудистая патология, в том числе хроническая сердечная недостаточность, является основной причиной заболеваемости и смертности пациентов, перенёсших рак, что ограничивает продолжительность их жизни. Проведён скрининг 4700 литературных источников из баз данных «Scopus», «Web of Science», «PubMed/MedLine», «The CochraneLibrary» по ключевым словам «anthracycline-induced cardiotoxicity», «cardiooncology», «cancer therapy-related cardiac dysfunction», «sacubitril/valsartan» за последние 10 лет. В обзоре на основе анализа высоко цитируемых статей изложены современные представления о кардиотоксичности антрациклинов, её механизмах и возможностях коррекции, в том числе с использованием сакубитрила/валсартана.

Due to the increased effectiveness of oncology treatments, cardiovascular disease, including chronic heart failure, is a major cause of morbidity and mortality in cancer survivors, limiting their life expectancy. Screening of 4700 literary sources from the databases "Scopus", "Web of Science", "PubMed / MedLine", "The CochraneLibrary" was carried out for the keywords "anthracycline-induced cardiotoxicity", "cardiooncology", "cancer therapy-related cardiac dysfunction", "sacubitril/valsartan" for the last 10 years. The review, based on the analysis of highly cited articles, outlines the current understanding of the cardiotoxicity of anthracyclines, its mechanisms and possibilities for correction, including the use of sacubitril/valsartan.

обзоркардиотоксичностьиндуцированная антрациклиномкардиоонкологиядисфункция сердцасвязанная с терапией ракасакубитрил/валсартанreviewanthracycline-induced cardiotoxicitycardiooncologycancer therapy-related cardiac dysfunctionsacubitril/valsartanИсследование не имело спонсорской поддержкиReferencesBychowski J, Sobiczewski W. Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies. Cancer Med. 2023;12(13):14545-14555. doi: 10.1002/cam4.5980Bychowski J, Sobiczewski W. Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies. Cancer Med. 2023 Apr 27. doi: 10.1002/cam4.5980. Online ahead of printLyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26. doi: 10.3389/fcvm.2020.00026Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26. doi: 10.3389/fcvm.2020.00026Sobczuk P, Czerwińska M, Kleibert M, Cudnoch-Jędrzejewska A. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2022;27(1):295-319. doi: 10.1007/s10741-020-09977-1Sobczuk P, Czerwińska M, Kleibert M, Cudnoch-Jędrzejewska A. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2022;27(1):295-319. doi: 10.1007/s10741-020-09977-1Attar A, Behnagh AK, Hosseini M, Amanollahi F, Shafiekhani P, Kabir A. Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials. Cardiovasc Ther. 2022;2022:8367444. doi: 10.1155/2022/8367444Attar A, Behnagh AK, Hosseini M, Amanollahi F, Shafiekhani P, Kabir A. Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials. Cardiovasc Ther. 2022;2022:8367444. doi: 10.1155/2022/8367444McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi: 10.1056/NEJMoa1409077McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi: 10.1056/NEJMoa1409077McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. 2020. doi: 10.15829/1560-4071-2020-4083Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020;6(1):24. doi: 10.1186/s40959-020-00078-4Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020;6(1):24. doi: 10.1186/s40959-020-00078-4Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445. doi: 10.1177/1179546819866445Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445. doi: 10.1177/1179546819866445Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280-299. doi: 10.1093/eurheartj/ehab674Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280-299. doi: 10.1093/eurheartj/ehab674Al-Malky HS, Al Harthi SE, Osman AM. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26(2):434-444. doi: 10.1177/1078155219877931Al-Malky HS, Al Harthi SE, Osman AM. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26(2):434-444. doi: 10.1177/1078155219877931Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. doi: 10.1002/cncr.11407Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. doi: 10.1002/cncr.11407Mauro C, Capone V, Cocchia R, Cademartiri F, Riccardi F, Arcopinto M, et al. Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways. J Clin Med. 2023;12(4):1612. doi: 10.3390/jcm12041612Al-Malky HS, Al Harthi SE, Osman AM. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26(2):434-444. doi: 10.1177/1078155219877931Sobiborowicz-Sadowska AM, Kamińska K, Cudnoch-Jędrzejewska A. Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. Cancers (Basel). 2023;15(1):312. doi: 10.3390/cancers15010312Mauro C, Capone V, Cocchia R, Cademartiri F, Riccardi F, Arcopinto M, et al. Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways. J Clin Med. 2023;12(4):1612. doi: 10.3390/jcm12041612Oikawa M, Ishida T, Takeishi Y. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. J Cardiol. 2023;81(3):253-259. doi: 10.1016/j.jjcc.2022.04.006Sobiborowicz-Sadowska AM, Kamińska K, Cudnoch-Jędrzejewska A. Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. Cancers (Basel). 2023;15(1):312. doi: 10.3390/cancers15010312Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I, et al. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023;12(4):659. doi: 10.3390/cells12040659Oikawa M, Ishida T, Takeishi Y. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. J Cardiol. 2023;81(3):253-259. doi: 10.1016/j.jjcc.2022.04.006Uusküla-Reimand L, Wilson MD. Untangling the roles of TOP2A and TOP2B in transcription and cancer. Sci Adv. 2022;8(44):eadd4920. doi: 10.1126/sciadv.add4920Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I, et al. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023;12(4):659. doi: 10.3390/cells12040659Kong CY, Guo Z, Song P, Zhang X, Yuan YP, Teng T, et al. Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death. Int J Biol Sci. 2022;18(2):760-770. doi: 10.7150/ijbs.65258Uusküla-Reimand L, Wilson MD. Untangling the roles of TOP2A and TOP2B in transcription and cancer. Sci Adv. 2022;8(44):eadd4920. doi: 10.1126/sciadv.add4920D'Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A, et al. The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. Oxid Med Cell Longev. 2020;2020:5732956. doi: 10.1155/2020/5732956Kong CY, Guo Z, Song P, Zhang X, Yuan YP, Teng T, et al. Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death. Int J Biol Sci. 2022;18(2):760-770. doi: 10.7150/ijbs.65258Wu L, Wang L, Du Y, Zhang Y, Ren J. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends Pharmacol Sci. 2023;44(1):34-49. doi: 10.1016/j.tips.2022.10.003D'Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A, et al. The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. Oxid Med Cell Longev. 2020;2020:5732956. doi: 10.1155/2020/5732956Bagchi AK, Malik A, Akolkar G, Zimmer A, Belló-Klein A, De Angelis K, et al. Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. Biochim Biophys Acta Mol Cell Res. 2021;1868(7):119039. doi: 10.1016/j.bbamcr.2021.119039Wu L, Wang L, Du Y, Zhang Y, Ren J. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends Pharmacol Sci. 2023;44(1):34-49. doi: 10.1016/j.tips.2022.10.003Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J Cardiol. 2022;80(2):125-132. doi: 10.1016/j.jjcc.2022.01.001Bagchi AK, Malik A, Akolkar G, Zimmer A, Belló-Klein A, De Angelis K, et al. Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. Biochim Biophys Acta Mol Cell Res. 2021;1868(7):119039. doi: 10.1016/j.bbamcr.2021.119039Bartlett JJ, Trivedi PC, Pulinilkunnil T. Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol. 2017;104:1-8. doi: 10.1016/j.yjmcc.2017.01.007Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J Cardiol. 2022;80(2):125-132. doi: 10.1016/j.jjcc.2022.01.001Mitry MA, Laurent D, Keith BL, Sira E, Eisenberg CA, Eisenberg LM, et al. Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am J Physiol Cell Physiol. 2020;318(2):C380-C391. doi: 10.1152/ajpcell.00073.2019Bartlett JJ, Trivedi PC, Pulinilkunnil T. Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol. 2017;104:1-8. doi: 10.1016/j.yjmcc.2017.01.007Feng J, Wu Y. Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity. Am J Cardiovasc Drugs. 2023;23(3):231-246. doi: 10.1007/s40256-023-00573-wMitry MA, Laurent D, Keith BL, Sira E, Eisenberg CA, Eisenberg LM, et al. Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am J Physiol Cell Physiol. 2020;318(2):C380-C391. doi: 10.1152/ajpcell.00073.2019Xie S, Ran Y, Wang X, Zhang Y, Fu Q, Ren Y, et al. Diagnostic potential of routine brain MRI and high-resolution, multi-contrast vessel wall imaging in the detection of internal carotid artery dissection. Front Neurol. 2023;14:1165453. doi: 10.3389/fneur.2023.1165453Feng J, Wu Y. Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity. Am J Cardiovasc Drugs. 2023;23(3):231-246. doi: 10.1007/s40256-023-00573-wReis-Mendes A, Padrão AI, Duarte JA, Gonçalves-Monteiro S, Duarte-Araújo M, Remião F, et al. Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice. Biomolecules. 2021;11(11):1725. doi: 10.3390/biom11111725Xie S, Ran Y, Wang X, Zhang Y, Fu Q, Ren Y, et al. Diagnostic potential of routine brain MRI and high-resolution, multi-contrast vessel wall imaging in the detection of internal carotid artery dissection. Front Neurol. 2023;14:1165453. doi: 10.3389/fneur.2023.1165453Trofenciuc NM, Bordejevic AD, Tomescu MC, Petrescu L, Crisan S, Geavlete O, et al. Toll-like receptor 4 (TLR4) expression is correlated with T2* iron deposition in response to doxorubicin treatment: cardiotoxicity risk assessment. Sci Rep. 2020;10(1):17013. doi: 10.1038/s41598-020-73946-9Reis-Mendes A, Padrão AI, Duarte JA, Gonçalves-Monteiro S, Duarte-Araújo M, Remião F, et al. Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice. Biomolecules. 2021;11(11):1725. doi: 10.3390/biom11111725Dos Santos Arruda F, Tomé FD, Miguel MP, de Menezes LB, Nagib PRA, Campos EC, et al. Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game. Curr Pharm Des. 2019;25(2):109-118. doi: 10.2174/1381612825666190312110836Trofenciuc NM, Bordejevic AD, Tomescu MC, Petrescu L, Crisan S, Geavlete O, et al. Toll-like receptor 4 (TLR4) expression is correlated with T2* iron deposition in response to doxorubicin treatment: cardiotoxicity risk assessment. Sci Rep. 2020;10(1):17013. doi: 10.1038/s41598-020-73946-9Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484Dos Santos Arruda F, Tomé FD, Miguel MP, de Menezes LB, Nagib PRA, Campos EC, et al. Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game. Curr Pharm Des. 2019;25(2):109-118. doi: 10.2174/1381612825666190312110836de Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484Hasinoff BB, Patel D, Wu X. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane. Cardiovasc Toxicol. 2020;20(3):312-320. doi: 10.1007/s12012-019-09554-5de Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2Kourek C, Touloupaki M, Rempakos A, Loritis K, Tsougkos E, Paraskevaidis I, et al. Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. J Cardiovasc Dev Dis. 2022;9(8):259. doi: 10.3390/jcdd9080259Hasinoff BB, Patel D, Wu X. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane. Cardiovasc Toxicol. 2020;20(3):312-320. doi: 10.1007/s12012-019-09554-5Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318-32. doi: 10.1200/JCO.1997.15.4.1318Kourek C, Touloupaki M, Rempakos A, Loritis K, Tsougkos E, Paraskevaidis I, et al. Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. J Cardiovasc Dev Dis. 2022;9(8):259. doi: 10.3390/jcdd9080259Bansal N, Adams MJ, Ganatra S, Colan SD, Aggarwal S, Steiner R, et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;5:18. doi: 10.1186/s40959-019-0054-5Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318-32. doi: 10.1200/JCO.1997.15.4.1318Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671-80. doi: 10.1093/eurheartj/ehw022Bansal N, Adams MJ, Ganatra S, Colan SD, Aggarwal S, Steiner R, et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;5:18. doi: 10.1186/s40959-019-0054-5Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671-80. doi: 10.1093/eurheartj/ehw022Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi: 10.1016/j.biopha.2021.111708Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072Spiazzi BF, Naibo RA, Wayerbacher LF, Piccoli GF, Farenzena LP, Londero TM, et al. Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023;198:110621. doi: 10.1016/j.diabres.2023.110621Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi: 10.1016/j.biopha.2021.111708Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions. JACC Basic Transl Sci. 2022;8(1):88-105. doi: 10.1016/j.jacbts.2022.05.010Spiazzi BF, Naibo RA, Wayerbacher LF, Piccoli GF, Farenzena LP, Londero TM, et al. Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023;198:110621. doi: 10.1016/j.diabres.2023.110621Fu S, Chang Z, Luo L, Deng J. Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure. Curr Top Med Chem. 2019;19(20):1850-1866. doi: 10.2174/1568026619666190826163536Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions. JACC Basic Transl Sci. 2022;8(1):88-105. doi: 10.1016/j.jacbts.2022.05.010Martyniak A, Tomasik PJ. A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2022;13(1):16. doi: 10.3390/diagnostics13010016Fu S, Chang Z, Luo L, Deng J. Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure. Curr Top Med Chem. 2019;19(20):1850-1866. doi: 10.2174/1568026619666190826163536Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017;108:138-148. doi: 10.1016/j.yjmcc.2017.06.003Martyniak A, Tomasik PJ. A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2022;13(1):16. doi: 10.3390/diagnostics13010016Boutagy NE, Feher A, Pfau D, Liu Z, Guerrera NM, Freeburg LA, et al. Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity. JACC CardioOncol. 2020;2(5):774-787. doi: 10.1016/j.jaccao.2020.09.007Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017;108:138-148. doi: 10.1016/j.yjmcc.2017.06.003Dindaş F, Güngör H, Ekici M, Akokay P, Erhan F, Doğduş M, et al. Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway. Anatol J Cardiol. 2021;25(11):821-828. doi: 10.5152/AnatolJCardiol.2021.356Boutagy NE, Feher A, Pfau D, Liu Z, Guerrera NM, Freeburg LA, et al. Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity. JACC CardioOncol. 2020;2(5):774-787. doi: 10.1016/j.jaccao.2020.09.007Yu C, Li D, Li Z, Yu D, Zhai G. Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits. Acta Pharm. 2021;71(3):473-484. doi: 10.2478/acph-2021-0030Dindaş F, Güngör H, Ekici M, Akokay P, Erhan F, Doğduş M, et al. Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway. Anatol J Cardiol. 2021;25(11):821-828. doi: 10.5152/AnatolJCardiol.2021.356Dankowski R, Sacharczuk W, Łojko-Dankowska A, Nowicka A, Szałek-Goralewska A, Szyszka A. Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity. Kardiol Pol. 2021;79(9):1040-1041. doi: 10.33963/KP.a2021.0052Yu C, Li D, Li Z, Yu D, Zhai G. Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits. Acta Pharm. 2021;71(3):473-484. doi: 10.2478/acph-2021-0030Martín-García A, Díaz-Peláez E, Martín-García AC, Sánchez-González J, Ibáñez B, Sánchez PL. Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Rev Esp Cardiol (Engl Ed). 2020;73(3):268-269. doi: 10.1016/j.rec.2019.07.006Dankowski R, Sacharczuk W, Łojko-Dankowska A, Nowicka A, Szałek-Goralewska A, Szyszka A. Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity. Kardiol Pol. 2021;79(9):1040-1041. doi: 10.33963/KP.a2021.0052Канорский С.Г., Павловец В.П. Первый опыт применения валсартана/сакубитрила у женщин с сердечной недостаточностью и раком молочной железы, получающих адъювантную химиотерапию антрациклинами. Медицинский совет. 2019;(16):42-48. doi: 10.21518/2079-701X-2019-16-42-48Martín-García A, Díaz-Peláez E, Martín-García AC, Sánchez-González J, Ibáñez B, Sánchez PL. Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Rev Esp Cardiol (Engl Ed). 2020;73(3):268-269. doi: 10.1016/j.rec.2019.07.006Канорский С.Г., Павловец В.П. Cакубитрил/валсартан против кандесартана у женщин с сердечной недостаточностью, получающих адъювантную химиотерапию рака молочной железы, - можно ли констатировать антиаритмический эффект? Вестник аритмологии. 2020;27(3):34-41. doi: 10.35336/VA-2020-3-34-41Канорский С.Г., Павловец В.П. Первый опыт применения валсартана/сакубитрила у женщин с сердечной недостаточностью и раком молочной железы, получающих адъювантную химиотерапию антрациклинами. Медицинский совет. 2019;(16):42-48. Kanorskiy S.G., Pavlovets V.P. First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy. Meditsinskiy sovet = Medical Council. 2019;(16):42-48. (In Russ.) doi: 10.21518/2079-701X-2019-16-42-48Mecinaj A, Gulati G, Heck SL, Holte E, Fagerland MW, Larsen AI, et al. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology. 2021;7(1):33. doi: 10.1186/s40959-021-00115-wКанорский С.Г., Павловец В.П. Cакубитрил/валсартан против кандесартана у женщин с сердечной недостаточностью, получающих адъювантную химиотерапию рака молочной железы, - можно ли констатировать антиаритмический эффект? Вестник аритмологии. 2020;27(3):34-41. Kanorskii SG, Pavlovets VP. Sacubitril/valsartan versus candesartan in women with heart failure receiving adjuvant therapy for breast cancer - is there any antiarrhythmic effect? Journal of Arrhythmology. 2020;27(3):34-41. doi.org/10.35336/VA-2020-3-34-41Mecinaj A, Gulati G, Heck SL, Holte E, Fagerland MW, Larsen AI, et al. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology. 2021;7(1):33. doi: 10.1186/s40959-021-00115-wMecinaj A, Gulati G, Heck SL, Holte E, Fagerland MW, Larsen AI, et al. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology. 2021;7(1):33. doi: 10.1186/s40959-021-00115-w

The authors declare that there are no conflicts of interest present.